DNMT1 expression partially dictates 5-Azacytidine sensitivity and correlates with RAS/MEK/ERK activity in gastric cancer cells

References

• Zhao S, Allis CD, Wang GG. The language of chromatin modification in human cancers. Nat Rev Cancer. 2021;21(7):413–13. doi: 10.1038/s41568-021-00357-x
   PubMed Web of Science ®Google Scholar
• Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128(4):683–692. doi: 10.1016/j.cell.2007.01.029
   PubMed Web of Science ®Google Scholar
• Lyko F. The DNA methyltransferase family: a versatile toolkit for epigenetic regulation. Nat Rev Genet. 2018;19(2):81–92. doi: 10.1038/nrg.2017.80
   PubMed Web of Science ®Google Scholar
• Gnyszka A, Jastrzebski Z, Flis S. DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer. Anticancer Res. 2013;33:2989–2996.
   PubMed Web of Science ®Google Scholar
• Cowan LA, Talwar S, Yang AS. Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors. Epigenomics. 2010;2(1):71–86. doi: 10.2217/epi.09.44
   PubMed Web of Science ®Google Scholar
• Song J, Teplova M, Ishibe-Murakami S, et al. Structure-based mechanistic insights into DNMT1-mediated maintenance DNA methylation. Science. 2012;335(6069):709–712. doi: 10.1126/science.1214453
   PubMed Web of Science ®Google Scholar
• Hino R, Uozaki H, Murakami N, et al. Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma. Cancer Res. 2009;69:2766–2774. doi: 10.1158/0008-5472.CAN-08-3070
   PubMed Web of Science ®Google Scholar
• Chen W, Gao N, Shen Y, et al. Hypermethylation downregulates Runx3 gene expression and its restoration suppresses gastric epithelial cell growth by inducing p27 and caspase3 in human gastric cancer. J Gastroenterol Hepatol. 2010;25(4):823–831. doi: 10.1111/j.1440-1746.2009.06191.x
   PubMed Web of Science ®Google Scholar
• Mutze K, Langer R, Schumacher F, et al. DNA methyltransferase 1 as a predictive biomarker and potential therapeutic target for chemotherapy in gastric cancer. Eur J Cancer. 2011;47:1817–1825. doi: 10.1016/j.ejca.2011.02.024
   PubMed Web of Science ®Google Scholar
• Zhang X, Yashiro M, Ohira M, et al. Synergic antiproliferative effect of DNA methyltransferase inhibitor in combination with anticancer drugs in gastric carcinoma. Cancer Sci. 2006;97:938–944. doi: 10.1111/j.1349-7006.2006.00253.x
   PubMed Web of Science ®Google Scholar
• Lavoie H, Gagnon J, Therrien M. ERK signalling: a master regulator of cell behaviour, life and fate, nature reviews. Mol Cell Biol. 2020;21(10):607–632. doi: 10.1038/s41580-020-0255-7
   Google Scholar
• Samatar AA, Poulikakos PI. Targeting RAS-ERK signalling in cancer: promises and challenges, nature reviews. Drug Discovery. 2014;13:928–942. doi: 10.1038/nrd4281
   Google Scholar
• Lawrence MC, Jivan A, Shao C, et al. The roles of MAPKs in disease. Cell Res. 2008;18:436–442. doi: 10.1038/cr.2008.37
   PubMed Web of Science ®Google Scholar
• Kamisawa T, Wood LD, Itoi T, et al. Pancreatic cancer. Lancet. 2016;388(10039):73–85. doi: 10.1016/S0140-6736(16)00141-0
   PubMed Web of Science ®Google Scholar
• Nagarajan N, Bertrand D, Hillmer AM, et al. Whole-genome reconstruction and mutational signatures in gastric cancer. Genome Bio. 2012;13:R115. doi: 10.1186/gb-2012-13-12-r115
   PubMed Web of Science ®Google Scholar
• Wong GS, Zhou J, Liu JB, et al. Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat Med. 2018;24:968–977. doi: 10.1038/s41591-018-0022-x
   PubMed Web of Science ®Google Scholar
• Liu H, Zhang Z, Han Y, et al. The FENDRR/FOXC2 axis contributes to multidrug resistance in gastric cancer and correlates with poor prognosis. Front Oncol. 2021;11:634579. doi: 10.3389/fonc.2021.634579
   PubMed Web of Science ®Google Scholar
• Lu R, Wang X, Chen ZF, et al. Inhibition of the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway decreases DNA methylation in colon cancer cells. J Biol Chem. 2007;282(16):12249–12259. doi: 10.1074/jbc.M608525200
   PubMed Web of Science ®Google Scholar
• Issa JP. Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection. Nat Clin Pract Oncology. 2005;2(1):S24–29. doi: 10.1038/ncponc0355
   PubMedGoogle Scholar
• Thomas X. DNA methyltransferase inhibitors in acute myeloid leukemia: discovery, design and first therapeutic experiences. Expert Opin Drug Discov. 2012;7(11):1039–1051. doi: 10.1517/17460441.2012.722618
   PubMed Web of Science ®Google Scholar
• Connolly RM, Li H, Jankowitz RC, et al. Combination epigenetic therapy in advanced breast cancer with 5-azacitidine and Entinostat: A Phase II National cancer Institute/Stand up to cancer study. Clin Cancer Res: An Official J Am Ass Cancer Res. 2017;23(11):2691–2701. doi: 10.1158/1078-0432.CCR-16-1729
   PubMed Web of Science ®Google Scholar
• Overman MJ, Morris V, Moinova H, et al. Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. Oncotarget. 2016;7:67495–67506. doi: 10.18632/oncotarget.11317
   PubMedGoogle Scholar
• Lee V, Wang J, Zahurak M, et al. A Phase I trial of a guadecitabine (SGI-110) and irinotecan in metastatic colorectal cancer patients previously exposed to irinotecan. Clin Cancer Res. 2018;24:6160–6167. doi: 10.1158/1078-0432.CCR-18-0421
   PubMed Web of Science ®Google Scholar
• Juergens RA, Wrangle J, Vendetti FP, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discovery. 2011;1:598–607. doi: 10.1158/2159-8290.CD-11-0214
   PubMed Web of Science ®Google Scholar
• Tsai HC, Li H, Van Neste L, et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell. 2012;21(3):430–446. doi: 10.1016/j.ccr.2011.12.029
   PubMed Web of Science ®Google Scholar
• Stewart ML, Tamayo P, Wilson AJ, et al. KRAS genomic status predicts the sensitivity of ovarian cancer cells to decitabine. Cancer Res. 2015;75(14):2897–2906. doi: 10.1158/0008-5472.CAN-14-2860
   PubMed Web of Science ®Google Scholar
• Beyrouthy MJ, Garner KM, Hever MP, et al. High DNA methyltransferase 3B expression mediates 5-aza-deoxycytidine hypersensitivity in testicular germ cell tumors. Cancer Res. 2009;69(24):9360–9366. doi: 10.1158/0008-5472.CAN-09-1490
   PubMed Web of Science ®Google Scholar
• Yu J, Qin B, Moyer AM, et al. DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Investig. 2018;128(6):2376–2388. doi: 10.1172/JCI97924
   PubMed Web of Science ®Google Scholar
• Stresemann C, Brueckner B, Musch T, et al. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res. 2006;66(5):2794–2800. doi: 10.1158/0008-5472.CAN-05-2821
   PubMed Web of Science ®Google Scholar
• Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer. 2008;123:8–13. doi: 10.1002/ijc.23607
   PubMed Web of Science ®Google Scholar
• Serra RW, Fang M, Park SM, et al. A KRAS-directed transcriptional silencing pathway that mediates the CpG island methylator phenotype. Elife. 2014;3:e02313. doi: 10.7554/eLife.02313
   PubMed Web of Science ®Google Scholar
• Wajapeyee N, Malonia SK, Palakurthy RK, et al. Oncogenic RAS directs silencing of tumor suppressor genes through ordered recruitment of transcriptional repressors. Genes Dev. 2013;27(20):2221–2226. doi: 10.1101/gad.227413.113
   PubMed Web of Science ®Google Scholar
• Huang J, Stewart A, Maity B, et al. RGS6 suppresses Ras-induced cellular transformation by facilitating Tip60-mediated Dnmt1 degradation and promoting apoptosis. Oncogene. 2014;33(27):3604–3611. doi: 10.1038/onc.2013.324
   PubMed Web of Science ®Google Scholar
• Gazin C, Wajapeyee N, Gobeil S, et al. An elaborate pathway required for Ras-mediated epigenetic silencing. Nature. 2007;449(7165):1073–1077. doi: 10.1038/nature06251
   PubMed Web of Science ®Google Scholar
• Calvisi DF, Ladu S, Conner EA, et al. Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer. J Hepatol. 2011;54(2):311–319. doi: 10.1016/j.jhep.2010.06.036
   PubMed Web of Science ®Google Scholar
• Ordway JM, Williams K, Curran T. Transcription repression in oncogenic transformation: common targets of epigenetic repression in cells transformed by Fos, Ras or Dnmt1. Oncogene. 2004;23(21):3737–3748. doi: 10.1038/sj.onc.1207483
   PubMed Web of Science ®Google Scholar
• Ma TM, Sun LP, Dong NN, et al. Protein expression trends of DNMT1 in gastrointestinal diseases: from benign to precancerous lesions to cancer. World J Gastrointest Oncol. 2019;11:1141–1150. doi: 10.4251/wjgo.v11.i12.1141
   PubMed Web of Science ®Google Scholar
• Niwa T, Tsukamoto T, Toyoda T, et al. Inflammatory processes triggered by Helicobacter pylori infection cause aberrant DNA methylation in gastric epithelial cells. Cancer Res. 2010;70:1430–1440. doi: 10.1158/0008-5472.CAN-09-2755
   PubMed Web of Science ®Google Scholar
• Niwa T, Toyoda T, Tsukamoto T, et al. Prevention of Helicobacter pylori-induced gastric cancers in gerbils by a DNA demethylating agent. Cancer Prev Res. 2013;6:263–270. doi: 10.1158/1940-6207.CAPR-12-0369
   PubMed Web of Science ®Google Scholar
• Liao X, Siu MK, Chan KY, et al. Hypermethylation of RAS effector related genes and DNA methyltransferase 1 expression in endometrial carcinogenesis. Int J Cancer. 2008;123:296–302. doi: 10.1002/ijc.23494
   PubMed Web of Science ®Google Scholar
• Calvisi DF, Ladu S, Gorden A, et al. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Investig. 2007;117(9):2713–2722. doi: 10.1172/JCI31457
   PubMed Web of Science ®Google Scholar
• Jin H, Wang X, Ying J, et al. Epigenetic silencing of a Ca 2+ -regulated Ras GTPase-activating protein RASAL defines a new mechanism of Ras activation in human cancers. Proc Natl Acad Sci, USA. 2007;104:12353–12358. doi: 10.1073/pnas.0700153104
   PubMed Web of Science ®Google Scholar